{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:47:31Z","timestamp":1793281651656,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006324.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000}}],"reference-count":136,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006324.pub3","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T09:16:40Z","timestamp":1490347000000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia"],"prefix":"10.1002","volume":"2017","author":[{"given":"Sarah","family":"Barber","sequence":"first","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwaila","family":"Olotu","sequence":"additional","affiliation":[{"name":"Rampton Hospital; Psychiatry; Retford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Corsi","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"University of Oxford; Department of Psychiatry; Warneford Hospital Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD006324.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/JCP.0b013e318219cba3","article-title":"Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care a randomized, controlled trial","volume":"31","author":"Barbui","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006324.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JCP.0b013e318296884f","article-title":"Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial","volume":"33","author":"Cipriani","year":"2013","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02849987","article-title":"Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study","volume":"24","author":"Gen\u00e7","year":"2007","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0004|cit4","first-page":"119","article-title":"Clozapine combined with risperidone and sulpiride in treatment resistant schizophrenia","volume":"14","author":"Kong","year":"2001","journal-title":"Shandong Archives of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006324.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-0030-1254089","article-title":"Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone","volume":"43","author":"Kuwilsky","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0269881108089593","article-title":"Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial","volume":"23","author":"Zink","year":"2009","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0007|cit7","first-page":"4","article-title":"A comparative study of clozapine combined with ziprasidone or quetiapine for treatment resistant schizophrenia","volume":"27","author":"Wen","year":"2015","journal-title":"Medical Journal of Chinese People's Health"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-0028-1094313","article-title":"The clinical effect of clozapine","volume":"4","author":"Angst","year":"1971","journal-title":"Pharmakopsychiatrie und Neuropsychopharmakologie"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0009|cit9","unstructured":"Anil E Risperidone augmented with clozapine for schizophrenia Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0010|cit10","unstructured":"Anonymous Clinician's desktop reference for clinical & cost utility of latest antipsychotics cutlass www.iop.kcl.ac.uk\/iop\/extras\/cutlass\/Downloads\/cutlass.pdf"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2007-993209","article-title":"Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial","volume":"41","author":"Assion","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006324.pub3-BIB0012|cit12","first-page":"274","article-title":"A double-blind study on the effect of clozapine, penfluridol and chlorpromazine in the treatment of schizophrenia","volume":"21","author":"Bao","year":"1988","journal-title":"Chung Hua Shen Ching Ching Shen Ko Tsa Chih [Chinese Journal of Neurology and Psychiatry]"},{"issue":"3","key":"10.1002\/14651858.CD006324.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1192\/bjp.bp.113.125807","article-title":"Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes","volume":"203","author":"Barnes","year":"2013","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006324.pub3-BIB0014|cit14","first-page":"151","article-title":"Antipsychotic efficacy of trimipramine: double-blind comparison with a classical neuroleptic","volume":"30","author":"Bender","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Bilder RM Goldman RS Volavka J Czobor P Hoptman M Sheitman B Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; Whistler British Columbia, Canada 2001","DOI":"10.1016\/S0924-977X(01)80300-X"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0016|cit16","unstructured":"Bustillo J Lamotrigine for schizophrenia Stanley Foundation Research Programs 2009"},{"issue":"4","key":"10.1002\/14651858.CD006324.pub3-BIB0017|cit17","first-page":"316","article-title":"The control study of risperidone and clozapine for the treatment-resistant schizophrenia","volume":"3","author":"Cao","year":"2003","journal-title":"Chinese Journal of Medicine Research"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Chang JS Ahn YM Park HJ Lee KY Kim SH Kang UG Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial Journal of Clinical Psychiatry 2008 720 31","DOI":"10.4088\/JCP.v69n0505"},{"issue":"14","key":"10.1002\/14651858.CD006324.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/070674370505001404","article-title":"Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia","volume":"50","author":"Cooper","year":"2005","journal-title":"Canadian Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD006324.pub3-BIB0020|cit20","first-page":"176","article-title":"Ziprasidone combined with small dose of clozapine for 44 cases of treatment resistant schizophrenia","volume":"8","author":"Dai","year":"2014","journal-title":"For All Health"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0006-3223(94)90847-8","article-title":"Comparison of risperidone and clozapine on clinical and cognitive functions in psychotic disorders","volume":"35","author":"Daniel","year":"1994","journal-title":"Biological Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD006324.pub3-BIB0022|cit22","first-page":"1061","article-title":"Ziprasidone treatment of the first clinical diagnosis of schizophrenia","volume":"19","author":"\u8463\u592a\u65b0","year":"2007","journal-title":"Medical Journal of Chinese People's Health"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0023|cit23","unstructured":"Feifel D Oxytocin for schizophrenia Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.1016\/S0924-977X(08)70660-6","article-title":"Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response on clozapine","volume":"18","author":"Fleischhacker","year":"2008","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.eurpsy.2008.01.784","article-title":"Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study","volume":"23","author":"Fleischhacker","year":"2008","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0026|cit26","unstructured":"Freudenreich O Risperidone added to clozapine for schizophrenia Stanley Foundation Research Programs 2009"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00427742","article-title":"Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine","volume":"59","author":"Gerlach","year":"1978","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006324.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.4088\/JCP.v65n0513","article-title":"Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior","volume":"65","author":"Glick","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD006324.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1176\/ajp.153.12.1628","article-title":"D-cycloserine added to clozapine for patients with schizophrenia","volume":"153","author":"Goff","year":"1996","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0030|cit30","unstructured":"Goff D CX516 for schizophrenia Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0031|cit31","unstructured":"Gunduz-Bruce H Pimozide for schizophrenia Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0032|cit32","unstructured":"Haro J Amisulpride and quetiapine for schizophrenia Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S466","DOI":"10.1016\/S0924-977X(08)70692-8","article-title":"Adjunctive topiramate in hospitalized patients with chronic schizophrenia disorder","volume":"18","author":"Hebrani","year":"2008","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0034|cit34","unstructured":"Henderson D Rosiglitazone for schizophrenia Stanley Foundation Research Programs 2009"},{"issue":"5","key":"10.1002\/14651858.CD006324.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine alone versus clozapine and risperidone with refractory schizophrenia","volume":"354","author":"Honer","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006324.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/S0924-977X(07)70237-7","article-title":"A randomized controlled trial of antipsychotic polypharmacy: clozapine plus risperidone","volume":"17","author":"Honer","year":"2007","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00442562","article-title":"Predictors of response to clozapine therapy","volume":"99","author":"Honigfeld","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0038|cit38","volume-title":"Serum Level of Homocysteine in Patients with Schizophrenia [Masters thesis]","author":"Ji","year":"2005"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0920-9964(03)80474-7","article-title":"Clozapine augmentation with risperidone in refractory schizophrenia","volume":"60","author":"Josiassen","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0040|cit40","first-page":"168","article-title":"Quasi-experimental comparison of the efficacy of classical and atypical neuroleptics in acute schizophrenia with respect to their cognitive and emotional side effects","volume":"26","author":"Klieser","year":"1993","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006324.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","article-title":"Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study","volume":"27","author":"Kluge","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0042|cit42","first-page":"202","article-title":"Control study of loxapine succinate and clozapine on curative effects in treatment of schizophrenics","volume":"3","author":"Li","year":"2004","journal-title":"Health Psychology Journal"},{"issue":"12","key":"10.1002\/14651858.CD006324.pub3-BIB0043|cit43","first-page":"1274","article-title":"Fluphenazine decanoate combined clozapine treatment of refractory schizophrenia","volume":"20","author":"\u5218\u53cb\u593a","year":"2008","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"12","key":"10.1002\/14651858.CD006324.pub3-BIB0044|cit44","first-page":"1046","article-title":"A study of aripiprazole combined with clozapine in refractory schizophrenia","volume":"19","author":"Ma","year":"2007","journal-title":"Medical Journal of Chinese People's Health"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4088\/JCP.v59n0511","article-title":"Antipsychotics in treatment-refractory schizophrenia. In: Marder SR, chairperson. Atypical antipsychotic agents in the treatment of schizophrenia and other psychotic disorders. I. Unique patient populations","volume":"59","author":"Marder","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD006324.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1176\/ajp.156.7.1126","article-title":"Risperidone and clozapine for treatment-resistant schizophrenia","volume":"156","author":"Meltzer","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006324.pub3-BIB0047|cit47","first-page":"A17","article-title":"The effects of aripiprazole in combination with clozapine: patient functioning results from a double-blind, 16-week study in patients with schizophrenia (CN138-170)","volume":"22","author":"Millar","year":"2008","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1077-7229(98)80024-2","article-title":"Therapeutic effects of clozapine on tardive dyskinesia","volume":"1","author":"Nair","year":"1998","journal-title":"Cognitive and Behavioral Practice"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0049|cit49","unstructured":"NCT00628420 Safety study of ACP-104: to demonstrate the safety, tolerability, and pharmacokinetics www.clinicaltrials.gov\/show\/NCT00628420"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0050|cit50","unstructured":"NCT00649844 A study comparing the efficacy and tolerability of ziprasidone vs clozapine for the treatment of schizophrenia in patients who continue to have symptoms on or cannot tolerate other antipsychotic drugs www.clinicaltrials.gov\/show\/NCT00649844"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0051|cit51","unstructured":"NCT00654576 Effectiveness of antipsychotic combination with psychosocial intervention on outcome of patients with schizophrenia www.clinicaltrials.gov\/show\/NCT00654576"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0052|cit52","unstructured":"NCT00753051 Treat clozapine-resistant schizophrenia comparing between clozapine + haloperidol versus clozapine + electroconvulsive therapy (ECT) www.clinicaltrials.gov\/show\/NCT00753051"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0053|cit53","first-page":"81","article-title":"A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial","volume":"32","author":"Petit","year":"1996","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archpsyc.1994.03950020083008","article-title":"Clinical response to clozapine in patients with schizophrenia","volume":"51","author":"Pickar","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/ajp.156.1.145","article-title":"Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia","volume":"156","author":"Potkin","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1007\/BF00442568","article-title":"Clozapine in China: a review and preview of US\/PRC collaboration","volume":"99 Suppl","author":"Potter","year":"1989","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0057|cit57","first-page":"90","article-title":"Clozapine therapy in schizophrenia","volume":"16","author":"Qi","year":"1990","journal-title":"Chinese Journal of Nervous and Mental Disorders"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0058|cit58","unstructured":"Remington G Tetrabenazine for schizophrenia Stanley Foundation Research Programs 2009"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0059|cit59","unstructured":"Riera L Tandon R Stock EG Kujawa MJ Torbeyns AF Borian FE Broad effectiveness trial with aripiprazole 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland 2004"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0060|cit60","unstructured":"Riera L Hu R Stock E Nyilas M Torbeyns A Borian F Broad effectiveness trial with aripiprazole 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA 2004"},{"issue":"3","key":"10.1002\/14651858.CD006324.pub3-BIB0061|cit61","first-page":"211","article-title":"A control study of clozapine plus fluoxetine in schizophrenia with depressive symptoms","volume":"14","author":"Ruan","year":"2008","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0062|cit62","first-page":"38","article-title":"Comparative study on therapy of schizophrenia with quetiapine and clozapine","volume":"16","author":"Shen","year":"2004","journal-title":"Tianjin Pharmacy"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0063|cit63","first-page":"142","article-title":"A comparison trial of clozapine combined with perphenazine and single clozapine or perphenazine in treatment of schizophrenia","volume":"3","author":"Shun","year":"2000","journal-title":"Journal of Hebei Psychological Health"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1192\/bjp.171.6.569","article-title":"Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study","volume":"171","author":"Shiloh","year":"1997","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006324.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.jcp.0000084026.22282.5f","article-title":"Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder","volume":"23","author":"Small","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006324.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/hup.595","article-title":"Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study","volume":"19","author":"Stryjer","year":"2004","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0067|cit67","unstructured":"Uzun S Kozumplik O Mimica N Folnegovic-Smalc V Treatment with six different antipsychotics: evaluation by scale for the assessment of negative symptoms (SANS) 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland 2006"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2004.11.007","article-title":"Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation","volume":"76","author":"Volavka","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"23","key":"10.1002\/14651858.CD006324.pub3-BIB0069|cit69","first-page":"81","article-title":"Olanzapine on efficacy in patients with late-onset schizophrenia and quality of life","volume":"2","author":"\u4e07\u597d","year":"2007","journal-title":"\u4e2d\u56fd\u533b\u7597\u524d\u6cbf"},{"issue":"5","key":"10.1002\/14651858.CD006324.pub3-BIB0070|cit70","first-page":"230","article-title":"A comparative trial of efficacy of risperidone vs clozapine in treatment of refractory schizophrenia","volume":"11","author":"Wang","year":"2002","journal-title":"Chinese Journal of Pharmacoepidemiology"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0071|cit71","first-page":"113","article-title":"Differences in the clinical effect of various neuroleptics","volume":"14","author":"Welbel","year":"1980","journal-title":"Psychiatria Polska"},{"issue":"16","key":"10.1002\/14651858.CD006324.pub3-BIB0072|cit72","first-page":"78","article-title":"Joint clozapine risperidone treatment of refractory schizophrenia","volume":"2","author":"\u5f90\u5112\u747e","year":"2008","journal-title":"\u4e2d\u56fd\u73b0\u4ee3\u836f\u7269\u5e94\u7528"},{"issue":"4","key":"10.1002\/14651858.CD006324.pub3-BIB0073|cit73","first-page":"169","article-title":"The Chinese first-episode schizophrenia trial: design and methodology of the trial","volume":"24","author":"Xue","year":"2014","journal-title":"East Asian Archives Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4088\/JCP.v66n0109","article-title":"A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety","volume":"66","author":"Yagcioglu","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0075|cit75","first-page":"71","article-title":"Clozapine combined with chlorpromazine in the treatment of positive symptoms in schizophrenia","volume":"6","author":"Yang","year":"1994","journal-title":"Shanghai Psychological Medicine"},{"issue":"12","key":"10.1002\/14651858.CD006324.pub3-BIB0076|cit76","first-page":"2356","article-title":"The influencing of olanzapine to the blood drug level of clozapine and the treatment effect of schizophrenia","volume":"35","author":"Zhang","year":"2008","journal-title":"Modern Preventive Medicine"},{"issue":"14","key":"10.1002\/14651858.CD006324.pub3-BIB0077|cit77","first-page":"1709","article-title":"60 patients with schizophrenia negative symptoms combined application of clozapine and clozapine compared the efficacy of paroxetine","volume":"29","author":"\u5f20\u4ec1\u51ef","year":"2008","journal-title":"Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao]"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0078|cit78","first-page":"120","article-title":"A controlled clinical study of the effect on ECG QT when using clozapine alone and in combination","volume":"26","author":"Zhang","year":"2013","journal-title":"Journal of Sichuan Mental Health"},{"issue":"23","key":"10.1002\/14651858.CD006324.pub3-BIB0079|cit79","first-page":"1878","article-title":"Quetiapine combined clozapine in the treatment of negative symptoms of schizophrenia","volume":"13","author":"\u90d1\u666f\u8389","year":"2007","journal-title":"Medical Recapitulate"},{"issue":"4","key":"10.1002\/14651858.CD006324.pub3-BIB0080|cit80","first-page":"204","article-title":"A controlled trial comparing chlorimipramine and sulpiride as adjunct to clozapine in the treatment of negative symptoms of schizophrenia","volume":"9","author":"Zhu","year":"1999","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0081|cit81","first-page":"15","article-title":"A study of clozapine combined with or without pipotiazine palmitate in refractory schizophrenia","volume":"12","author":"Zhu","year":"2002","journal-title":"Journal of Clinical Psychological Medicine"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0083|cit83","volume-title":"Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1984"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0084|cit84","volume-title":"Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1984"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0085|cit85","volume-title":"Practice Guidelines for the Treatment of Patients with Schizophrenia","author":"American Psychiatric Association","year":"2004"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/schbul\/sbn030","article-title":"Does the addition of a second antipsychotic drug improve clozapine treatment?","volume":"35","author":"Barbui","year":"2009","journal-title":"Schizophrenia Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD006324.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/JCP.0b013e318219cba3","article-title":"Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care a randomized, controlled trial","volume":"31","author":"Barbui","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006324.pub3-BIB0089|cit89","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0091|cit91","first-page":"233","article-title":"Extrapyramidal Symptom Rating Scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Science"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006324.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1192\/bjp.166.5.650","article-title":"A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients","volume":"166","author":"Day","year":"1995","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0094|cit94","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"6","key":"10.1002\/14651858.CD006324.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/eb-2014-101813","article-title":"Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective","volume":"17","author":"Dold","year":"2014","journal-title":"Evidence Based Mental Health"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0098|cit98","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0101|cit101","first-page":"222","article-title":"The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia","volume":"25","author":"Fleischhacker","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0102|cit102","first-page":"876","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"149","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0103|cit103","unstructured":"GRADE Working Group, McMaster University GRADEpro 2004"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0105|cit105","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale of depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0108|cit108","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0109|cit109","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0110|cit110","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD006324.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"9896","key":"10.1002\/14651858.CD006324.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD006324.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00406-016-0715-4","article-title":"Network meta-analyses should be the highest level of evidence in treatment guidelines","volume":"266","author":"Leucht","year":"2016","journal-title":"European Archive of Psychiatry Clinical Neuroscience"},{"issue":"Suppl","key":"10.1002\/14651858.CD006324.pub3-BIB0116|cit116","first-page":"334","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"76","author":"Lingj\u00e6rde","year":"1987","journal-title":"Acta Psychatrica Scandinavica"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/eb-2015-102088","article-title":"A primer on network meta-analysis with emphasis on mental health","volume":"18","author":"Mavridis","year":"2015","journal-title":"Evidence Based Mental Health"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0119|cit119","unstructured":"NCT00224315 Clozapine-augmentation with ziprasidone or risperidone, a randomized, prospective trial clinicaltrials.gov\/show\/NCT00224315"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0120|cit120","unstructured":"National Institute for Health and Care Excellence Psychosis and schizophrenia in adults: prevention and management www.nice.org.uk\/guidance\/cg178"},{"issue":"10","key":"10.1002\/14651858.CD006324.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1745-6215-10-31","article-title":"Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia","volume":"15","author":"Nos\u00e8","year":"2009","journal-title":"Trials"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0123|cit123","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"10","key":"10.1002\/14651858.CD006324.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/M15-2367","article-title":"Network meta-analysis for clinical practice guidelines: a case study on first-line medical therapies for primary open-angle glaucoma","volume":"164","author":"Rouse","year":"2016","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0125|cit125","volume-title":"Modern Psychometrics","author":"Rust","year":"1989"},{"issue":"3","key":"10.1002\/14651858.CD006324.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0127|cit127","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"2","key":"10.1002\/14651858.CD006324.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1176\/appi.ajp.2015.15030332","article-title":"Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia","volume":"173","author":"Stroup","year":"2016","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2011.09.016","article-title":"Treatment resistant schizophrenia and response to antipsychotics: a review","volume":"133","author":"Suzuki","year":"2011","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006324.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/026988110001400411","article-title":"Refractory schizophrenia and atypical antipsychotics","volume":"14","author":"Taylor","year":"2000","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006324.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.2011.01792.x","article-title":"Augmentation of clozapine with a second antipsychotic - a meta-analysis","volume":"125","author":"Taylor","year":"2012","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD006324.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"7","key":"10.1002\/14651858.CD006324.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD006324.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0269881108089593","article-title":"Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial","volume":"23","author":"Zink","year":"2009","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006324.pub3-BIB0136|cit136","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006324.pub2","article-title":"Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia","author":"Cipriani","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006324.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T02:48:09Z","timestamp":1710730089000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006324.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":136,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006324.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,23]]}}}